Claims for Patent: 6,878,703

Summary for Patent: 6,878,703

Title:	Pharmaceutical composition
Abstract:	A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: ##STR1## The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
Inventor(s):	Sada; Toshio (Tokyo, JP), Mizuno; Makoto (Funabashi, JP)
Assignee:	Sankyo Company, Limited (Tokyo, JP)
Application Number:	10/442,874
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,878,703
Patent Claims:	1. A method for treating hypertension comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of each of (i) an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I): ##STR10## a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of said ester thereof, and (ii) a diuretic which is hydrochlorothiazide. 2. The method according to claim 1, wherein the warm-blooded animal is a human. 3. The method according to claim 2, wherein the angiotensin II receptor antagonist is the compound of the formula (I) or a pharmacologically acceptable ester hereof. 4. The method according to claim 2, wherein the angiotensin II receptor antagonist is a pharmacologically acceptable ester of the compound of the formula (I). 5. The method according to claim 2, wherein the angiotensin II receptor antagonist is the pivaloyloxymethyl ester, phthalidyl ester, or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I). 6. The method according to claim 2, wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of th formula (I). 7. The method according to claim 2, wherein the diuretic further comprises one or more diuretics selected from the group consisting of methylclothiazide, benzyl-hydrochlorothiazide, trichlormethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide. 8. The method according to claim 2, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1. 9. The method according to claim 3, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1. 10. The method according to claim 5, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1. 11. The method according to claim 2, wherein the compound of the formula (I) is administered at least once a day in an amount of 0.5 to 1,000 mg and the diuretic is administered at least once a day in an amount of 0.05 to 1,500 mg. 12. The method according to claim 2, wherein the compound of the formula (I) is administered at least once a day in an amount of 1 to 100 mg and the diuretic is administered at least once a day in an amount of 5 to 300 mg. 13. The method according to claim 6, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1. 14. The method according to claim 6, wherein the compound of the formula (I) is administered at least once a day in an amount of 0.5 to 1,000 mg and the diuretic is administered at least once a day in an amount of 0.05 to 1,500 mg. 15. The method according to claim 6, wherein the compound of the formula (I) is administered at least once a day in an amount of 1 to 100 mg and the diuretic is administered at least once a day in an amount of 5 to 300 mg.